Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 5:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 3,231 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Blood draw (at diagnosis) Clear all
Withdrawn Phase 2 Interventional

Lenalidomide in Treating Patients With High-Risk Chronic Lymphocytic Leukemia

NCT01271283
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage IV Chronic Lymphocytic Leukemia
Interventions
Diagnostic Laboratory Biomarker Analysis, Lenalidomide
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Sep 29, 2026, 5:22 PM EDT
Completed No phase listed Observational

Maternal-fetal Immune Responses to Fetal Surgery

NCT04484441
View directory record Official record
Conditions
Spina Bifida, Congenital Diaphragmatic Hernia, Lower Urinary Tract Obstructive Syndrome, Myelomeningocele
Interventions
Blood and placenta specimen collection.
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
3
States / cities
Rochester, Minnesota • Cincinnati, Ohio • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Sep 29, 2026, 5:22 PM EDT
Terminated Phase 2 Interventional Results available

Temodar (Temozolomide), Bevacizumab, Lithium and Radiation for High Grade Glioma

NCT01105702
View directory record Official record
Conditions
Brain Cancer
Interventions
Temozolomide, Bevacizumab, Lithium Carbonate, Radiation
Drug · Radiation
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
Summit, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 3, 2016 · Synced Sep 29, 2026, 5:22 PM EDT
Completed Not applicable Interventional

Physical Activity as Self-Management Approach to Improve Health Outcomes in AML

NCT02584296
View directory record Official record
Conditions
Leukemia, Myeloid, Monocytic
Interventions
BSMA
Behavioral
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 5, 2017 · Synced Sep 29, 2026, 5:22 PM EDT
Withdrawn No phase listed Observational

Personalizing Immune Checkpoint Inhibitor Therapy

NCT03409341
View directory record Official record
Conditions
Lung Cancer Stage IV
Interventions
Blood and tumor tissue analysis, Clinical response.
Other
Lead sponsor
Holy Cross Hospital, Maryland
Other
Eligibility
18 Years to 70 Years
Timeline
2019 – 2020
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 23, 2020 · Synced Sep 29, 2026, 5:22 PM EDT
Recruiting No phase listed Observational

Clinical Microbial Species & Antibiotic Resistance ID in ED Patients Presenting With Infection - is Rapid ID Possible & Accurate?

NCT01904188
View directory record Official record
Conditions
Sepsis, Systemic Inflammatory Response Syndrome, Infection Mixed, Infection, Bacterial, Infection, Fungal, Infection, Coronavirus, Antibiotic Resistance Genes, Human Genome Analysis
Interventions
Gene Z or other rapid diagnostic techniques developed in our lab (as of 2018 not using Gene Z - now using In-Dx along with other developed techniquesregularly)
Device
Lead sponsor
Michigan State University
Other
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2032
U.S. locations
2
States / cities
Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Sep 29, 2026, 5:22 PM EDT
Not listed Phase 4 Interventional

A Study to Evaluate the Benefit of Octagam 5%® in Subjects With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)

NCT03348618
View directory record Official record
Conditions
Pediatric Acute-Onset Neuropsychiatric Syndrome, Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections
Interventions
IVIG
Biological
Lead sponsor
IMMUNOe Research Centers
Industry
Eligibility
4 Years to 16 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
Centennial, Colorado • Papillion, Nebraska • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Sep 29, 2026, 5:22 PM EDT
Recruiting Phase 2 Interventional

Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer

NCT05941520
View directory record Official record
Conditions
Breast Atypical Hyperplasia, Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ
Interventions
Acolbifene Hydrochloride, Biospecimen Collection, Mammography, Questionnaire Administration, Random Periareolar Fine-Needle Aspiration, Tamoxifen
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
35 Years and older · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
4
States / cities
Duarte, California • Chicago, Illinois • Kansas City, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 29, 2026, 5:22 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase I/II Thymus Transplantation With Immunosuppression #950

NCT00579527
View directory record Official record
Conditions
DiGeorge Anomaly, Complete DiGeorge Anomaly, Complete Atypical DiGeorge Anomaly, Complete DiGeorge Syndrome, Complete Atypical DiGeorge Syndrome
Interventions
Cultured Thymus Tissue for Implantation (CTTI), Cultured Thymus Tissue Implantation and Parental Parathyroid Transplantation, Blood Draw, Rabbit anti-thymocyte globulin, Cyclosporine, Tacrolimus, Methylprednisolone or Prednisolone, Daclizumab, Mycophenolate mofetil
Biological · Other · Procedure + 1 more
Lead sponsor
Sumitomo Pharma Switzerland GmbH
Industry
Eligibility
Not listed
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 24, 2022 · Synced Sep 29, 2026, 5:22 PM EDT
Active, not recruiting Phase 2 Interventional

A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors

NCT04931342
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Ipatasertib, Cobimetinib, Trastuzumab Emtansine, Atezolizumab, Bevacizumab, Paclitaxel, Giredestrant, Abemaciclib, Inavolisib, Palbociclib, Letrozole, Olaparib, Luteinizing Hormone-Releasing Hormone (LHRH) Agonists, Cyclophosphamide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older · Female only
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
8
States / cities
San Francisco, California • St Louis, Missouri • Charlotte, North Carolina + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 29, 2026, 5:22 PM EDT
Recruiting Not applicable Interventional

Utilization of Lung Ultrasound Score in Decision for Minimally Invasive Surfactant Administration

NCT07442669
View directory record Official record
Conditions
Respiratory Distress Syndrome, Newborn, Respiratory Distress Syndrome in Premature Infant
Interventions
Lung ultrasound
Diagnostic Test
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
27 Weeks to 34 Weeks
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 29, 2026, 5:22 PM EDT
Not yet recruiting Not applicable Interventional

MH-Rx Study (Baby on Board: Check-in on You, Your Medication, & Your Blood Pressure)

NCT07842341
View directory record Official record
Conditions
Hypertensive Disorders of Pregnancy, Chronic Hypertension in Pregnancy, Gestational Hypertension
Interventions
Community Health Worker (CHW)/Social Worker (SW)-led non-medical health related needs (NMHRN) intervention + Clinician-Led Medication Therapy Management (MTM) with remote blood pressure monitoring, Active Comparator (Control group)
Behavioral
Lead sponsor
Texas Southern University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Sep 29, 2026, 5:22 PM EDT
Completed Not applicable Interventional Results available

Ketogenic Diet (KD) in Alcoholism

NCT03255031
View directory record Official record
Conditions
Alcoholism
Interventions
Ketogenic Diet (KD), Standard American (SA) Meals and Shakes
Other
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 16, 2024 · Synced Sep 29, 2026, 5:22 PM EDT
Recruiting Phase 3 Interventional

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

NCT05947851
View directory record Official record
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Chronic Lymphocytic, Small-Cell Lymphoma, Lymphoma, Small Lymphocytic, CLL, SLL
Interventions
Nemtabrutinib, Venetoclax, Rituximab
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
735 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2035
U.S. locations
18
States / cities
Springdale, Arkansas • Long Beach, California • Clermont, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Sep 29, 2026, 5:22 PM EDT
Completed Not applicable Interventional

Multiple Myeloma/Chronic Lymphocytic Leukemia Coach RCT

NCT05928156
View directory record Official record
Conditions
Multiple Myeloma, Chronic Lymphocytic Leukemia
Interventions
Myeloma Coach or CLL Coach Mobile App, Springboard Beyond Cancer informational website
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 2, 2023 · Synced Sep 29, 2026, 5:22 PM EDT
Withdrawn No phase listed Observational

Trial of Prostate Cancer Patients Undergoing Active Surveillance With or Without MRI-Guided Management

NCT01838265
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma
Interventions
Transrectal Ultrasound-Guided Biopsy, MRI Ultrasound Biopsy, Expanded Prostate Cancer index Composite Questionnaire, Short-Form 12 of Health Related Quality of Life Questionnaire, Memorial Anxiety Scale for Prostate Cancer, Plasma/Serum Sample for biomarkers, Urine Sample for Biomarkers, Blood Tests for Blood Urea Nitrogen and Creatinine, Blood Test for Serum PSA
Procedure · Behavioral
Lead sponsor
University of Miami
Other
Eligibility
35 Years to 75 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 7, 2014 · Synced Sep 29, 2026, 5:22 PM EDT
Recruiting No phase listed Observational

Biology of Young Lung Cancer Study: The YOUNG LUNG Study

NCT05265429
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Small Cell Lung Carcinoma, NUT Carcinoma
Interventions
Data and Specimen Collection
Genetic
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
15 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
4
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Sep 29, 2026, 5:22 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

A Recovery and Lifespan Study Using INTERCEPT Red Blood Cells Prepared Using the INTERCEPT Blood System for RBCs With AS-1

NCT07015437
View directory record Official record
Conditions
Healthy Subjects
Interventions
INTERCEPT Blood System for RBCs, Infusion of autologous radiolabeled RBCs
Device · Other
Lead sponsor
Cerus Corporation
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
2
States / cities
Cincinnati, Ohio • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 20, 2026 · Synced Sep 29, 2026, 5:22 PM EDT
Completed Not applicable Interventional

Active Surveillance Exercise Clinical Trial

NCT02435472
View directory record Official record
Conditions
Localized Prostate Cancer, Active Surveillance for Prostate Cancer
Interventions
Exercise, Cardiopulmonary Exercise Test (CPET)
Behavioral · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 10, 2025 · Synced Sep 29, 2026, 5:22 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Non-invasive Characterization of Systemic Microvascular Reactivity by Near-infrared Diffuse Optical Spectroscopy in COVID-19 Patients

NCT04689477
View directory record Official record
Conditions
COVID-19, Endothelial Function
Interventions
Vascular occlusion test
Device
Lead sponsor
Corporacion Parc Tauli
Other
Eligibility
18 Years and older
Enrollment
612 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2022 · Synced Sep 29, 2026, 5:22 PM EDT
Terminated Phase 2 Interventional Results available

Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma

NCT03401853
View directory record Official record
Conditions
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma
Interventions
Laboratory Biomarker Analysis, Pembrolizumab, Rituximab, Obinutuzumab
Other · Biological
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 21, 2025 · Synced Sep 29, 2026, 5:22 PM EDT
Terminated Phase 1 Interventional

A Trial to Assess the Effects of Prazosin or Propranolol on Blood Pressure in the Presence of Brexpiprazole/Sertraline

NCT05189977
View directory record Official record
Conditions
Post-traumatic Stress Disorder (PTSD)
Interventions
Propranolol, Prazosin
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 22, 2024 · Synced Sep 29, 2026, 5:22 PM EDT
Active, not recruiting No phase listed Observational

Genetic Analysis in Blood and Tumor Samples From Patients With Advanced or Metastatic Estrogen Receptor Positive and HER2 Negative Breast Cancer Receiving Palbociclib and Endocrine Therapy

NCT03281902
View directory record Official record
Conditions
Advanced Breast Carcinoma, Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
Interventions
Biopsy, Biospecimen Collection, Laboratory Biomarker Analysis
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 29, 2026, 5:22 PM EDT
Active, not recruiting Phase 2 Interventional

Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial

NCT05715281
View directory record Official record
Conditions
Advanced Rare Malignant Solid Neoplasm, Rare Malignant Solid Neoplasm, Refractory Rare Malignant Solid Neoplasm
Interventions
Atezolizumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Tiragolumab
Biological · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Bethesda, Maryland • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Sep 29, 2026, 5:22 PM EDT